Trial Profile
A 13-Week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 15 Sep 2017 Results assessing the impact of lixisenatide dose range on glycaemic outcomes in three studies (ACT6011, DRI6012 and LixiLan-O), presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 01 Sep 2010 Results published in Diabetic Medicine.
- 01 Oct 2009 Results of a pharmcodynamic substudy presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).